PAFOLACIANINE SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C61H63N9O17S4.4Na
Molecular Weight	1414.422
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].CC1(C)\C(=C/C=C2\CCCC(\C=C\C3=[N+](CCCCS([O-])(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C([O-])=O)C=C5)N(CCCCS([O-])(=O)=O)C9=C1C=C(C=C9)S([O-])(=O)=O

InChI

InChIKey=LRVBSDMJFVZFHH-NFVAJSDSSA-J

InChI=1S/C61H67N9O17S4.4Na/c1-60(2)46-33-44(90(81,82)83)22-24-49(46)69(28-5-7-30-88(75,76)77)51(60)26-16-38-10-9-11-39(17-27-52-61(3,4)47-34-45(91(84,85)86)23-25-50(47)70(52)29-6-8-31-89(78,79)80)54(38)87-43-20-12-37(13-21-43)32-48(58(73)74)66-56(71)40-14-18-41(19-15-40)63-35-42-36-64-55-53(65-42)57(72)68-59(62)67-55;;;;/h12-27,33-34,36,48H,5-11,28-32,35H2,1-4H3,(H9-,62,63,64,66,67,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86);;;;/q;4*+1/p-4/t48-;;;;/m0..../s1

HIDE SMILES / InChI

Molecular Formula	C61H63N9O17S4
Molecular Weight	1322.463
Charge	-4
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	3
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800041273 | https://clinicaltrials.gov/ct2/show/NCT02872701 | http://www.checkorphan.org/news/first-patient-treated-in-pivotal-phase-3-trial-to-evaluate-otl38-in-the-detection-of-ovarian-cancer | https://www.purdue.edu/newsroom/releases/2016/Q4/molecule-that-lights-up-cancer-accelerating-toward-fda-approval.html

OTL-0038 or OTL-38, a fluorescent-labelled folate receptor-α (FRα) targeted imaging agent that accumulates in vivo in tumor cells expressing FR. OTL38 is currently in ongoing Phase 3 clinical trial in ovarian cancer and successfully completed phase 2 clinical trial in lung cancer. OTL38 is being evaluated for its ability to help surgeons locate and remove hard-to-find cancerous lesions that are often widespread. In 2014, the OTL-38 molecule was granted orphan drug status which can be given to the maker of a drug that treats rare conditions or diseases and offers protection from competition for a period of time. In addition, OTL-38 was studied in phase II clinical trials in the Netherlands for the diagnosis of endometriosis.

Originator

Approval Year

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

0.025 mg/kg of OTL38 (OTL-0038) in 250ml D5W infused intravenously over 60 minutes

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:30:40 GMT 2023` Edited by `admin` on `Sat Dec 16 10:30:40 GMT 2023`
Record UNII	4HUF3V875C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PAFOLACIANINE SODIUM

Official Name

English

PAFOLACIANINE SODIUM [USAN]

Common Name

English

3H-INDOLIUM, 2-(2-(2-(4-((2S)-2-((4-(((2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)AMINO)-2-CARBOXYETHYL)PHENOXY)-3-(2-(1,3-DIHYDRO-3,3-DIMETHYL-5-SULFO-1-(4-SULFOBUTYL)-2H-INDOL-2-YLIDENE)ETHYLIDENE)-1-CYCLOHEXEN-1-YL)ETHENYL)-3,3-DIMETH

Systematic Name

English

OTL38 TETRASODIUM

Code

English

CYTALUX

Brand Name

English

OTL0038 TETRASODIUM

Code

English

Pafolacianine tetrasodium

Common Name

English

OTL-0038 TETRASODIUM

Code

English

Pafolacianine tetrasodium [WHO-DD]

Common Name

English

OTL-38 TETRASODIUM

Code

English

2-(2-(2-(4-((2S)-2-(4-(((2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL)AMINO)BENZAMIDO)-2-CARBOXYETHYL)PHENOXY)-3-(2-(3,3-DIMETHYL-5-SULFO-1-(4-SULFOBUTYL)-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)ETHYLIDENE)CYCLOHEX-1-EN-1-YL)ETHENYL)-3,3-DIMETHYL-5-SULFO-1-(4-SU

Systematic Name

English

Code System Code Type Description

CAS

1628858-03-6